Identifying blood markers to predict treatment response in children with neuroblastoma
Official title: Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma
Funded at University of California, San Francisco · NIH-11061047 · Data updated 2026-11-12
This study is looking at how certain blood tests can help doctors understand which new treatments work best for kids with advanced neuroblastoma, making it easier and safer for them by using simple blood samples instead of more invasive tests.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $540,607 |
| NIH project number | 5R01CA285681-02 |
| Project ID | NIH-11061047 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged 0-11 years diagnosed with advanced neuroblastoma who are eligible for the clinical trial.
✕Less likely to help
Patients with neuroblastoma who are not eligible for the trial or those with early-stage disease may not benefit from this research.
What this research studies
This research investigates how specific blood markers can help predict how well children with advanced neuroblastoma will respond to new combination therapies. By analyzing samples from a clinical trial, researchers will look for circulating tumor DNA and cells that may indicate treatment effectiveness. This approach aims to minimize invasive procedures by using liquid biopsies, making it safer for young patients. The study will compare different treatment combinations to find the most effective options for these children.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for children with neuroblastoma.
How similar studies have gone: Previous studies have shown promise in using circulating biomarkers for treatment response in various cancers, indicating a potential for success in this novel approach.
Where this research is happening
-
University of California, San Francisco
San Francisco, United States Active
Researchers
- Principal investigator: Vo, Kieuhoa Tran — University of California, San Francisco
- Study coordinator: Vo, Kieuhoa Tran
Related research
Other NIH-funded projects on the same topics.
-
Computational and functional screens to find actionable neuroblastoma drivers
Researchers are using advanced computer analysis and lab tests to find new genes and drug targets in neuroblastoma, aiming to improve outcomes for children.
-
Understanding ATRX in neuroblastoma: new protein functions and treatment clues
A short, patient-friendly look at a study exploring how altered ATRX proteins in neuroblastoma might influence disease behavior and response to therapy.
-
Neuroblastoma and radiopharmaceuticals: understanding how targeted radiation affects kids’ tumors
A pediatric cancer grant studies how a targeted radiotherapy called 131I-MIBG affects tumor and surrounding cells in children with high-risk neuroblastoma.
-
Bispecific antibodies to help kids fight neuroblastoma and brain tumors
A pediatric-focused grant tests new bispecific antibodies that help the immune system attack childhood cancers like neuroblastoma and brain tumors.
-
ADEPT-STAR therapy for high risk neuroblastoma
A new cell-based therapy approach aims to help children with high-risk neuroblastoma by using off-the-shelf, donor-derived treatments.
-
MYCN and ferroptosis: a new vulnerability in pediatric neuroblastoma
A study in children with neuroblastoma looks at a new vulnerability called ferroptosis that could be exploited to more effectively treat tumors with the MYCN gene amplification.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.